NEW YORK – ImmunoScape said on Wednesday that it has raised $11 million in a funding round led by venture firm Anzu Partners.
The Singapore-based company will use the funds to expand its presence in the US market and to continue development and commercialization of its immune profiling platform, which uses mass cytometry to profile T-cell response in cancer and infectious disease.
ImmunoScape's focus is providing immune profiling to support development of cancer immunotherapies.
"To deliver on the promise of individualized medicine for cancer, the biopharma industry desperately needs more insight into every patient's unique immune system. ImmunoScape can deliver this, and we are delighted to support them," David Michael, managing partner of Anzu Partners, said in a statement.
The company, which was founded in 2017 as a spin-out of A*STAR of Singapore, is also involved in work with researchers at Massachusetts General Hospital, the University of Parma, and Duke-NUS studying immune responses to COVID-19 and has established collaborations with pharma firms developing vaccines against the disease including San Diego-based Arcturus.
University of Tokyo Edge Capital (UTEC) in Japan and NPR Holdings in Indonesia were also investors in the round.